Q1 EPS Estimates for Sana Biotechnology Cut by HC Wainwright

Sana Biotechnology, Inc. (NASDAQ:SANA) – Investment analysts at HC Wainwright lowered their Q1 2026 earnings per share estimates for shares of Sana Biotechnology in a research report issued to clients and investors on Wednesday, March 4th. HC Wainwright analyst E. Bodnar now forecasts that the company will post earnings per share of ($0.14) for the quarter, down from their prior forecast of ($0.08). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Sana Biotechnology’s current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Sana Biotechnology’s Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.13) EPS, FY2026 earnings at ($0.53) EPS, FY2027 earnings at ($0.59) EPS, FY2028 earnings at ($0.64) EPS and FY2029 earnings at ($0.66) EPS.

Several other research analysts also recently issued reports on SANA. Bank of America raised their price objective on shares of Sana Biotechnology from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sana Biotechnology in a research note on Monday, December 29th. Wall Street Zen lowered Sana Biotechnology from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. Wedbush boosted their price target on Sana Biotechnology from $5.00 to $6.00 and gave the company an “outperform” rating in a research report on Friday, November 7th. Finally, Zacks Research downgraded Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $7.83.

Sana Biotechnology Price Performance

SANA stock opened at $3.15 on Friday. The company has a fifty day moving average price of $4.25 and a 200 day moving average price of $4.13. Sana Biotechnology has a 12 month low of $1.26 and a 12 month high of $6.55. The company has a market cap of $840.64 million, a price-to-earnings ratio of -3.25 and a beta of 1.96.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.03).

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Nisa Investment Advisors LLC lifted its position in Sana Biotechnology by 673.8% in the second quarter. Nisa Investment Advisors LLC now owns 10,911 shares of the company’s stock valued at $30,000 after purchasing an additional 9,501 shares during the period. Mercer Global Advisors Inc. ADV purchased a new position in shares of Sana Biotechnology during the 3rd quarter worth approximately $36,000. TD Waterhouse Canada Inc. purchased a new position in shares of Sana Biotechnology during the 3rd quarter worth approximately $37,000. Lyell Wealth Management LP acquired a new stake in shares of Sana Biotechnology in the 3rd quarter valued at approximately $37,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in shares of Sana Biotechnology in the third quarter valued at approximately $39,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Key Sana Biotechnology News

Here are the key news stories impacting Sana Biotechnology this week:

• Positive Sentiment: HC Wainwright retained a “Buy” rating and a $7.00 price target on SANA even as it trimmed estimates — that continued institutional support can limit downside and suggests upside potential if execution improves. MarketBeat SANA
• Neutral Sentiment: Sana presented at the TD Cowen 46th Annual Health Care Conference (transcript available). Conference appearances increase management visibility to investors; the stock reaction will depend on any new data or timeline updates disclosed in the talk. TD Cowen Presentation Transcript
• Negative Sentiment: HC Wainwright cut EPS estimates across multiple quarters and out years (Q1–Q4 2026 and FY2026–2030 were revised lower), signaling slower expected progress or higher near-term spend — these reductions pressure the stock by lowering near- and medium-term earnings visibility. MarketBeat SANA (HC Wainwright notes)
• Negative Sentiment: Zacks downgraded SANA from “strong-buy” to “hold,” removing a strong buy-side endorsement and likely contributing to selling pressure from retail/quant strategies that track analyst momentum. Zacks TickerReport
• Negative Sentiment: Sana recently reported an EPS miss for the quarter (reported March 3), which combined with the analyst downgrades increases near-term uncertainty around execution and cash runway — a key concern for biotech investors. MarketBeat SANA (earnings)
• Negative Sentiment: A TipRanks piece highlights a newly disclosed risk tied to AI adoption (data, compliance, reputational risks). While not an immediate earnings driver, rising compliance risk can raise operating costs or distract management if issues emerge. TipRanks: AI Risk

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.